Trending in Rare Diseases: HYMPAVZI, LOJUXTA Approval and more

This edition highlights major developments across rare diseases, including the FDA expansion of HYMPAVZI for additional hemophilia populations and the European Commission approval of LOJUXTA for pediatric HoFH patients. Other updates include Health Canada’s priority review of FILSUVEZ, publication of Phase 2 RAINBOW data for nizubaglustat, encouraging clinical findings for asedebart and IMAAVY, a rare pediatric designation request for SkinJect, and orphan drug exclusivity granted to PAPZIMEOS. The recap spans regulatory, clinical, and market access developments across multiple rare disease areas.

Видео Trending in Rare Diseases: HYMPAVZI, LOJUXTA Approval and more канала LucidQuest